SavedAdd your journal

Journals / İstanbul Kuzey Klinikleri / 2021 / Cilt: 8 - Sayı: 3

The relation between visceral fat markers and cardiometabolic disease risks in psoriasis patients

Latife Uzun
Arzu Ataseven
Ruhusen Kutlu
Pages
203–211
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

RESULTS: LAP index, VAI, PAI, BMI, and TG levels were significantly high (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE: Psoriasis is a chronic, inflammatory disease that appears with variable trigger factors.
📊
Key Findings & Data:METHODS: A total of 203 subjects, 102 psoriasis patients and 101 healthy individuals, were included in the study.
💡
Conclusion & Impact:RESULTS: LAP index, VAI, PAI, BMI, and TG levels were significantly high (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

OBJECTIVE: Psoriasis is a chronic, inflammatory disease that appears with variable trigger factors. We know that obesity and other metabolic syndrome criteria are high in psoriasis patients. The aim of this study is to evaluate the relationship between visceral fat markers, risk of cardiometabolic disease, and psoriasis area severity index (PASI) in individuals with and without psoriasis. METHODS: A total of 203 subjects, 102 psoriasis patients and 101 healthy individuals, were included in the study. Lipid accumulation product (LAP) index, visceral adiposity index (VAI), plasma atherogenicity index (PAI), body mass index (BMI), PASI, triglyceride (TG), and high-density lipoprotein cholesterol (HDL-c) values were measured. RESULTS: LAP index, VAI, PAI, BMI, and TG levels were significantly high (p

🔖

Cite This Article

Uzun, L., Ataseven, A., Kutlu, R. (2022). The relation between visceral fat markers and cardiometabolic disease risks in psoriasis patients. İstanbul Kuzey Klinikleri, Cilt: 8 - Sayı: 3, 203–211. https://ajindex.com/articles/551272

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol 2017;31:205– 12
  2. Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2005;64 Suppl 2:ii65–8
  3. Sondermann W, Djeudeu Deudjui DA, Körber A, Slomiany U, Brinker TJ, Erbel R, et al. Psoriasis, cardiovascular risk factors and metabolic disorders: sex-specific findings of a population-based study. J Eur Acad Dermatol Venereol 2020;34:779–86
  4. Reich K. The concept of psoriasis as a systemic inflammation: implications for disease management. J Eur Acad Dermatol Venereol 2012;26 Suppl 2:3–11
  5. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006;298:321–8
  6. Günaydın A, Aytimur D, Özdemir F. Psoriasis and metabolic syndrome. Turkderm 2014:48:95–9
  7. Praveenkumar U, Ganguly S, Ray L, Nanda SK, Kuruvila S. Prevalence of metabolic syndrome in psoriasis patients and its relation to disease duration: a hospital based case-control study. J Clin Diagn Res 2016:10:WC01–5
  8. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006;55:829–35
  9. Ma C, Harskamp CT, Armstrong EJ, Armstrong AW. The association between psoriasis and dyslipidaemia: a systematic review. Br J Dermatol 2013;168:486–95
  10. Bremmer S, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Young M, et al; National Psoriasis Foundation. Obesity and psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2010;63:1058–69
  11. Duarte GV, Oliveira Mde F, Cardoso TM, Follador I, Silva TS, Cavalheiro CM, et al. Association between obesity measured by different parameters and severity of psoriasis. Int J Dermatol 2013;52:177–81
  12. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735–41
  13. Parisi R, Rutter MK, Lunt M, Young HS, Symmons DPM, Griffiths CEM, et al; Identification and management of psoriasis associated comorbidiTy (IMPACT) project team. Psoriasis and the risk of major cardiovascular events: cohort study using the clinical practice research datalink. J Invest Dermatol 2015;135:2189–97
  14. Ganguly S, Ray L, Kuruvila S, Nanda SK, Ravichandran K. Lipid accumulation product index as visceral o